Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19265466 | 0.86 | HTR7 (0.43) | CETPTSHRMAPK1HTR2AHTR2B | |
| SCHEMBL8626864 | 0.85 | CYP3A4 (0.55) | CETPTSHRMAPK1HTR2AHTR2B | |
| SCHEMBL5538898 | 0.84 | CETP (0.42) | CETPTSHRMAPK1HTR2AHTR2B | |
| SCHEMBL5541971 | 0.81 | HTR7 (0.42) | CETPTSHRMAPK1HTR2AHTR2B | |
| SCHEMBL171829 | 0.80 | TSHR (0.48) | CETPTSHRMAPK1HTR2AHTR2B | |
| SCHEMBL5281174 | 0.80 | TACR1 (0.44) | TSHRMAPK1HTR2AHTR2CCYP3A4 | |
| SCHEMBL30901511 | 0.80 | TSHR (0.48) | CETPTSHRMAPK1HTR2AHTR2B | |
| SCHEMBL27908520 | 0.80 | CETP (0.46) | CETPTSHRMAPK1HTR2AHTR2B | |
| SCHEMBL13153377 | 0.79 | CETP (0.41) | CETPTSHRMAPK1HTR2AHTR2B | |
| SCHEMBL5500471 | 0.79 | CYP3A4 (0.44) | CETPTSHRMAPK1HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021214315-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901154-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2021-10-27 | — | — | EP | disclosed |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (JP) | 2017-01-19 | — | — | US | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-8461209-B2 | Malonic acid sulfonamide derivative and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-06-11 | — | — | US | disclosed |
| EP-1697304-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | ELI LILLY AND COMPANY (IN) | 2007-04-12 | — | — | US | disclosed |
| EP-1697304-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005054176-A1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | CETP 4822/4885TSHR 351/4885MAPK1 3042/4885 |
| US-20070082907-A1 | Peroxisome proliferator activated receptor modulators | PPARG, PPARA, PPARD | CETP 211/4885TSHR 1550/4885MAPK1 1850/4885 |
| US-20170014419-A1 | MEDICAMENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS | AGTR2, MME, AGTR1 | CETP 2931/4885TSHR 1343/4885MAPK1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.